STOCK TITAN

BRAXIA SCIENTIFIC CORP - BRAXF STOCK NEWS

Welcome to our dedicated news page for BRAXIA SCIENTIFIC (Ticker: BRAXF), a resource for investors and traders seeking the latest updates and insights on BRAXIA SCIENTIFIC.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BRAXIA SCIENTIFIC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BRAXIA SCIENTIFIC's position in the market.

Rhea-AI Summary
Braxia Scientific Corp. Announces Financial Statements for Q3 2024, Revenue Growth, and Strategic Review
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
-
Rhea-AI Summary
Braxia Scientific Corp. announces the mandatory conversion of $2,935,714 in convertible debentures into 19,571,411 common shares at a conversion price of $0.15 per common share. The company specializes in providing innovative ketamine and psilocybin treatments for depression and related disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.29%
Tags
none
-
Rhea-AI Summary
Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), a medical research company offering innovative ketamine and psilocybin treatments for depression and related disorders, announced strong revenue growth and the initiation of a strategic review process. Revenue increased by 30.5% to $0.594 million for the three months ended September 30, 2023, and by 36.8% to $1.19 million for the six months ended September 30, 2023. However, the company reported a net loss of $0.275 million for the three months ended September 30, 2023, with a working capital deficit of $0.961 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Braxia Scientific Corp. reports Q1 2024 revenue increase of 44% to $0.600 million. Net loss decreases to $0.809 million. Cash and cash equivalents at $0.861 million with a working capital deficit of $0.753 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
BRAXIA SCIENTIFIC CORP

OTC:BRAXF

BRAXF Rankings

BRAXF Stock Data

2.05M
263.91M
11.49%
0.02%
Outpatient Mental Health and Substance Abuse Centers
Health Care and Social Assistance
Link
United States of America
Port Moody